Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...

(Reuters) - Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Merck & Co. Inc. closed $34.98 below its 52-week high ($134.63), which the company achieved on June 25th.

Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, ...

Merck and Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Disruptive analytics’ Substack by Magnus Ofstad. In this ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

Keytruda sales account for roughly 40% of Merck’s revenue, and the company has been focused on the 2028 patent expiration for ...

President-elect Donald Trump's pick to lead HHS has a long history of discounting and peddling misinformation about the HPV ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...